Recruiting

Indapamide for Reducing Disability Progression in Adults with Primary and Secondary Progressive Multiple Sclerosis

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

Multiple Sclerosis is a condition in which the body's immune system mistakenly attacks the protective coating of nerve fibers, leading to problems with movement, balance, sensation, and thinking. In the forms called primary progressive multiple sclerosis and secondary progressive multiple sclerosis, disability tends to get worse steadily over time. The study will give participants a daily oral tablet of Indapamide, a medicine normally used to lower blood pressure, to see if it can slow this decline.

The purpose of the study is to determine whether the medication can prevent or lessen further disability in people with these disease forms. Participants will take the tablet each day for about 12 months and will visit the clinic at the start, midway, and at the end to check safety and to measure walking ability using a simple 25‑foot walk test called the T25FW. No other experimental treatment will be given.

During the year, participants will keep a short diary of any new symptoms or side effects and will have routine blood checks to monitor health. The final visit will include the same walking test and a review of overall condition. The study is open‑label, meaning the medication being taken is known to both the doctors and the participants.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Baseline assessment
During the first visit after joining, baseline measurements are recorded. these include a timed 25‑foot walk (t25fw) to establish your initial level of disability.
Step 2
Start medication
You begin taking the study medication, indapamide tablets. each tablet contains 2.5 mg of indapamide hemihydrate and is taken by mouth (oral route). the exact schedule and duration are defined by the trial protocol.
Step 3
Regular follow‑up visits
You attend scheduled visits throughout the study. at each visit, health status and any side effects are reviewed, and additional measurements may be performed as required by the trial.
Step 4
12‑month assessment
After approximately 12 months of treatment, the timed 25‑foot walk (t25fw) is performed again. the result is compared with the baseline measurement to determine whether disability has worsened by 20 % or more.
Step 5
Study completion
The trial ends for you after the final assessment. all data collected are used to evaluate the effectiveness of indapamide in slowing disability progression.

Who can join the trial?

7 criteria

Written informed consent obtained – you must sign a form that shows you understand the study and agree to take part.
Age between 18 and 65 years.
Diagnosed with primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) according to the latest medical guidelines – a doctor must have confirmed you have one of these types of MS.
Screening Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5 – this is a standard test that rates how much disability you have; your score must fall in this range.
Screening timed 25‑foot walk (average of two tries):
- For PPMS, the walk must take 5 seconds or longer.
- For SPMS, the walk must take 9 seconds or longer.
- Women who could become pregnant must use effective methods of contraception – a reliable birth‑control method is required.

Who cannot join the trial?

15 criteria

Having kidney problems with a measured kidney function (eGFR) lower than 30 ml/min per 1.73 m².
Starting the muscle‑relaxing medicines Baclofen or Tizanidine at any time during the study.
Increasing the dose of Baclofen or Tizanidine while taking part in the study.
Receiving Botulinum toxin injections in the leg muscles during the study.
Using disease‑modifying drugs such as siponimod, ocrelizumab, natalizumab or similar treatments for relapsing‑remitting MS.
Having a recent brain or spinal‑cord MRI (within the past 6 months) that shows new lesions or uses a contrast agent called gadolinium to highlight active disease.
Taking corticosteroids (a type of anti‑inflammatory medicine) at the same time as the study medication.
Having serious liver problems (called hepatic impairment) before the study or developing them while in the study.
Having abnormal results on the screening blood or urine tests that are considered clinically important.
Having an irregular heartbeat (cardiac arrhythmia).
Having a prolonged heart‑electrical timing called the QT interval – specifically a corrected QT (QTc) longer than 450 ms for men or 470 ms for women at the first screening, or longer than 500 ms on any later heart test.
Being pregnant or currently breast‑feeding.
Being allergic to or unable to tolerate the study drug indapamide.
Using the medicines Fampridine or 4‑aminopyridine at any time.
Starting the medicines Fampridine or 4‑aminopyridine during the study.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Amsterdam UMC
Responsive
Amsterdam, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Indapamide is a medication taken by mouth in tablet form. In this trial it is being tested to see if it can help slow down the worsening of disability in people with primary or secondary progressive multiple sclerosis. Researchers are giving participants this drug to evaluate whether it can protect against further loss of function and keep symptoms from getting worse over time.

INDAPAMIDE HEMIHYDRATE

What is already known about the treatment

Indapamide Tablets 2.5mg - Indapamide tablets are taken orally as a coated tablet, usually one 2.5 mg dose each day. It is a well‑known medicine that has been used for many years to treat high blood pressure and fluid retention, and its safety and effects are well described in medical literature. In this trial the drug is being tested to see if it can slow disability progression in primary and secondary progressive multiple sclerosis. Indapamide works by blocking sodium channels in the kidneys, helping the body remove extra salt and water, and it is classified as a thiazide‑like diuretic.

Investigated diseases

Multiple Sclerosis - Multiple Sclerosis is a condition that affects the protective covering of nerve fibers in the brain and spinal cord. Over time, the covering becomes damaged, which can slow down the flow of information between the brain and the rest of the body. The disease often starts with mild symptoms such as tingling or weakness, and these signs can become more noticeable as the condition advances. In some people the disease follows a pattern where symptoms slowly get worse without clear relapses, known as primary progressive multiple sclerosis. Others may experience periods of stability followed by a steady increase in disability, called secondary progressive multiple sclerosis. The overall course varies, but the damage to nerve coverings tends to accumulate gradually.